Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive secures US$1.4mln from US defence department for biohazard-detection device

Genedrive is further developing its handheld device to detect a broader range of biohazard targets
The device has had successful field trials

Genedrive PLC (LON:GDR) has secured a further US$1.4mln in funding from the US Department of Defence for its handheld biohazard-detection device programme.

The extra funding follows successful field trials on the portable device whereby officials assessed its potential to check for hazards such as biological warfare agents.

Genedrive will use the funds to further develop the device to detect a broader range of biohazard targets across multiple cartridges.

READ: Genedrive making “good progress” as revenues rise across board, Hep-C assay nears EU approval

The company said the aim of the programme is to develop a “cost-effective system that would allow multiple units and tests to be deployed for field use”.

The latest funding brings the total it has received from the Department of Defence to US$6.5mln.

The next stage of the programme is expected to generate about US$1.4mln in development income for the year to 30 June 2018.

"This next phase of field testing will help to further validate and confirm the characteristics of the Genedrive system: portability, flexibility and accuracy,” said Genedrive’s chief executive, David Budd.

 “The evaluation will be far reaching, rigorous and, if successful, it will be a clear validation of the Genedrive unit as a robust and easily deployable hand held device for pathogen and disease detection."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use